Robert Hariri

Robert Hariri

Company: Celularity

Job title: CEO


Preclinical and Clinical Development of Human Placental Hematopoietic Stem Cell Derived NK Cells (CYNK001) for the Treatment of COVID-19 4:20 pm

• Celularity has developed a novel proprietary GMP procedure that enables the scalable production of an off-the-shelf, allogeneic NK cell therapy (CYNK-001) • Combining pathogenic mechanism of coronavirus, existing and validated research results, we hypothesize adoptive CYNK001 therapy may provide the antiviral activities thereby serve as effective solutions for COVID-19 patients • Discuss the initial…Read more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.